Alnylam Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Alnylam Pharmaceuticals (ALNY).

Price Target Range — 7 Quarters

Analyst Consensus — 22 Analysts

1S.Buy

19Buy

2Hold

Consensus RatingBuy# Analysts22Avg. Consensus PT$418Upside to Avg. PT+82.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 30, 2026	JP Morgan	Jessica Fye	PT Cut	Overweight	$375→$369
Sep 21, 2026	HC Wainwright & Co.	Patrick R. Trucchio	Maintained	Buy	$455
Sep 8, 2026	Jefferies	Faisal Khurshid	PT Raise	Hold	$230→$260
Sep 2, 2026	HC Wainwright & Co.	Patrick R. Trucchio	Maintained	Buy	$455
Aug 19, 2026	BMO Capital	David Lebowitz	Initiate	Outperform	$318
Aug 14, 2026	Wells Fargo	Derek Archila	PT Cut	Equal-Weight	$316→$256
Aug 4, 2026	Truist Securities	Danielle Brill	PT Cut	Buy	$410→$315
Aug 4, 2026	HC Wainwright & Co.	Patrick R. Trucchio	PT Cut	Buy	$485→$455
Aug 3, 2026	Raymond James	Martin Auster	Upgrade	Outperform→Strong Buy	$420
Aug 3, 2026	Citigroup	Eric Joseph	PT Cut	Buy	$380→$340
Aug 3, 2026	Barclays	Eliana Merle	PT Cut	Overweight	$527→$450
Jul 31, 2026	JP Morgan	Jessica Fye	PT Cut	Overweight	$400→$375
Jul 31, 2026	RBC Capital	Luca Issi	PT Cut	Outperform	$445→$350
Jul 31, 2026	Morgan Stanley	Michael Ulz	PT Cut	Equal-Weight	$400→$300
Jul 31, 2026	Oppenheimer	Kostas Biliouris	PT Cut	Outperform	$500→$350
Jul 31, 2026	Wells Fargo	Derek Archila	PT Cut	Equal-Weight	$377→$316
Jul 31, 2026	Stifel	Paul Matteis	PT Cut	Buy	$444→$318
Jul 31, 2026	Chardan Capital	Keay Nakae	Maintained	Buy	$425
Jul 30, 2026	Needham	Joseph Stringer	PT Cut	Buy	$510→$357
Jul 22, 2026	JP Morgan	Jessica Fye	PT Cut	Overweight	$420→$400

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
JP Morgan Maintains Overweight on Alnylam Pharmaceuticals, Lowers Price Target to $369

JP Morgan analyst Jessica Fye maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Overweight and lowers the price target from $375 to $369.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Alnylam Pharmaceuticals, Maintains $455 Price Target

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and maintains $455 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Alnylam Pharmaceuticals, Maintains $455 Price Target

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and maintains $455 price target.

Benzinga Newsdesk

This Alnylam Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

Top analysts change outlook on ALNY, AGMB, BMRN, BEKE, and IONS with ratings and price targets. Check out opinions and coverage on Benzinga.

Avi Kapoor

PRO
BMO Capital Initiates Coverage On Alnylam Pharmaceuticals with Outperform Rating, Announces Price Target of $318

BMO Capital analyst David Lebowitz initiates coverage on Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Outperform rating and announces Price Target of $318.

Benzinga Newsdesk

PRO
Wells Fargo Maintains Equal-Weight on Alnylam Pharmaceuticals, Lowers Price Target to $256

Wells Fargo analyst Derek Archila maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Equal-Weight and lowers the price target from $316 to $256.

Benzinga Newsdesk

Alnylam Pharmaceuticals Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Alnylam Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
JP Morgan Maintains Overweight on Alnylam Pharmaceuticals, Lowers Price Target to $369

PRO
HC Wainwright & Co. Reiterates Buy on Alnylam Pharmaceuticals, Maintains $455 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Alnylam Pharmaceuticals, Maintains $455 Price Target

This Alnylam Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

PRO
BMO Capital Initiates Coverage On Alnylam Pharmaceuticals with Outperform Rating, Announces Price Target of $318

PRO
Wells Fargo Maintains Equal-Weight on Alnylam Pharmaceuticals, Lowers Price Target to $256

People Also Watch

People Also Watch

Alnylam Pharmaceuticals Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Alnylam Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROJP Morgan Maintains Overweight on Alnylam Pharmaceuticals, Lowers Price Target to $369

PROHC Wainwright & Co. Reiterates Buy on Alnylam Pharmaceuticals, Maintains $455 Price Target

PROHC Wainwright & Co. Reiterates Buy on Alnylam Pharmaceuticals, Maintains $455 Price Target

This Alnylam Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

PROBMO Capital Initiates Coverage On Alnylam Pharmaceuticals with Outperform Rating, Announces Price Target of $318

PROWells Fargo Maintains Equal-Weight on Alnylam Pharmaceuticals, Lowers Price Target to $256

People Also Watch

People Also Watch

PRO
JP Morgan Maintains Overweight on Alnylam Pharmaceuticals, Lowers Price Target to $369

PRO
HC Wainwright & Co. Reiterates Buy on Alnylam Pharmaceuticals, Maintains $455 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Alnylam Pharmaceuticals, Maintains $455 Price Target

PRO
BMO Capital Initiates Coverage On Alnylam Pharmaceuticals with Outperform Rating, Announces Price Target of $318

PRO
Wells Fargo Maintains Equal-Weight on Alnylam Pharmaceuticals, Lowers Price Target to $256